SELLAS Life Sciences Group (SLS) is back on traders’ radar after fresh data from its leukemia program, including strong response rates and supportive FDA designations, helped spark a sharp move in the ...
Principal is secured and repaid through maturities of the SLS portfolio. Interest (7.5% p.a.) is paid from project revenues. Coverage ratios are maintained at a minimum of 125% of note value. Funds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback